Anti-VEGF therapy in proliferative diabetic retinopathy

Int Ophthalmol Clin. 2009 Spring;49(2):95-107. doi: 10.1097/IIO.0b013e31819fd84a.
No abstract available

Publication types

  • Review

MeSH terms

  • Angiogenesis Inhibitors / administration & dosage
  • Angiogenesis Inhibitors / pharmacokinetics
  • Angiogenesis Inhibitors / therapeutic use*
  • Animals
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / pharmacokinetics
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Aptamers, Nucleotide / administration & dosage
  • Aptamers, Nucleotide / pharmacokinetics
  • Aptamers, Nucleotide / therapeutic use*
  • Bevacizumab
  • Diabetic Retinopathy / complications
  • Diabetic Retinopathy / drug therapy*
  • Diabetic Retinopathy / pathology
  • Disease Models, Animal
  • Humans
  • Injections
  • Ranibizumab
  • Treatment Outcome
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors*
  • Vascular Endothelial Growth Factor A / metabolism
  • Vitreoretinopathy, Proliferative / drug therapy*
  • Vitreoretinopathy, Proliferative / etiology
  • Vitreoretinopathy, Proliferative / metabolism
  • Vitreous Body

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Aptamers, Nucleotide
  • Vascular Endothelial Growth Factor A
  • pegaptanib
  • Bevacizumab
  • Ranibizumab